Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached...

Related Keywords

United States ,Mccormick Place ,Illinois ,Chicago ,American ,Laura Morgan ,Myesha Lacy ,Matthewj Frigault ,Cellular Therapy Service At Mass ,International Myeloma Working Group ,American Society Of Clinical Oncology ,Mccormick Place Convention Center ,Drug Administration ,Cancer Center ,Instructor At Harvard Medical School ,Prnewswire Arcellx Inc ,Nasdaq ,Sam Brown Inc ,Exchange Commission ,Arcellx Inc ,Securities Exchange ,Clinical Oncology ,Assistant Director ,Cellular Therapy Service ,Mass General Cancer Center ,Harvard Medical School ,Rami Elghandour ,Chief Executive ,Presentation Details ,Refractory Multiple ,Harvard Medical ,Oral Abstract ,Hematologic Malignancies ,Plasma Cell ,Fast Track ,Orphan Drug ,Regenerative Medicine Advanced Therapy ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Quarterly Reports ,Current Reports ,Arcellx ,Nc ,